Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: The effects of an early therapeutic intervention

European Journal of Neurology

Volumn 14, Issue 3, 2007, Pages 282-289

  Grandas, F ^a   Hernandez B ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Novartis Farmacéutica S A   (Spain)

Author keywords

Early intervention; Entacapone; Long term effects; Parkinson's disease; Quality of life

Indexed keywords

AMANTADINE; BIPERIDEN; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; SELEGILINE; TRIHEXYPHENIDYL;

ABDOMINAL PAIN; ABNORMAL URINE COMPOSITION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; EARLY INTERVENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; SCORING SYSTEM; TREATMENT WITHDRAWAL; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL HALLUCINATION;

EID: 33847762823     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01635.x     Document Type: Article

References (42)

1. Marsden CD. Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1994; 57: 672-681.
2. Fahn S. 'On-off' phenomenon with levodopa therapy in parkinsonism. Neurology 1980; 24: 431-441.
3. Obeso JA, Grandas F, Vaamonde J et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989; 39(Suppl. 2): 11-19.
4. Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders 2004; 19: 997-1005.
5. Widnell KL, Comella C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Movement Disorders 2005; 20: S30-S37.
6. Nissinen E, Linden IB, Schultz E, Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O- methyltransferase inhibitor entacapone. Naunyn-Schmiedeberg's Archives of Pharmacology 1992; 346: 262-266.
7. Kaakkola S, Wurtman RJ. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Research 1992; 587: 241-249.
8. Keränen T, Gordin A, Harjola VP et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clinical Neuropharmacology 1993; 16: 145-156.
9. Kaakkola S, Teräväinen H, Ahtila S. Entacapone in combination with standard or controlled-release levodopa/cardidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. European Journal of Neurology 1995; 2: 341-347.
10. Nutt JG. Catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Lancet 1998; 351: 1221-1222.
11. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Annals of Neurology 1997; 42: 747-755.
12. Rinne UK, Larsen JP, Siden A, Worm-Petersen J, Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309-1314.
13. Myllyla VV, Kultalahti ER, Haapanieni H, Leinone M, FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. European Journal of Neurology 2001; 8: 53-60.
14. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, CELOMEN Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen Study). Acta Neurologica Scandinavica 2002; 105: 245-255.
15. Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K, ComQoL Study Group. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurologica Scandinavica 2005; 111: 21-28.
16. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000; 59: 1233-1250.
17. Haynes RB, Yao X, Degani A et al. Interventions to enhance medication adherence. Cochrane Database of Systematic Reviews 2005; 4: CD000011.
18. van Eijken M, Tsang S, Wensing M et al. Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs Aging 2003; 20: 229-240.
19. Bosworth HB, Olsen MK, Oddone EZ. Improving blood pressure control by tailored feedback to patients and clinicians. American Heart Journal 2005; 149: 795-803.
20. Contreras Em, García OV, Claros NM et al. Efficacy of telephone and mail intervention in patient compliance with antihypertensive drugs in hypertension. Blood Pressure 2005; 14: 151-158.
21. Lee M, Kemp JA, Canning A et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Archives of Internal Medicine 1999; 159: 2312-2316.
22. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short form Parkinson's disease questionnaire. Psychology and Health 1997; 12: 805-814.
23. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. Journal of Neurology 1998; 245(Suppl. 1): S10-S14.
24. Uppsala Monitoring Centre. Adverse Reaction Terminology. Uppsala: World Health Organization Collaborating Centre for International Drug Monitoring, 1999.
25. Gershanik O, Emre M, Bernhard G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2003; 27: 963-971.
26. Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I, F-01 Study Group. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: and open, multicenter study. European Neurology 2001; 45: 111-118.
27. Brooks DJ, Sagar H, the UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuation and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. Journal of Neurology, Neurosurgery, and Psychiatry 2003; 74: 1071-1079.
28. Schapira AH, Obeso JA, Olanow CW. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology 2000; 55: S65-S71.
29. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 2000; 68: 589-594.
30. Parashos SA, Wielinski CL, Kern JA. Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. Clinical Neuropharmacology 2004; 27: 119-123.
31. Kupsch A, Trottenberg T, Bremen D. Levodopa therapy with entacapone in daily clinical practice: results of a postmarketing surveillance study. Current medical research and opinion 2004; 20: 115-120.
32. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M, NOMESAFE Study Group. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. European Journal of Neurology 2003; 10: 137-146.
33. Adler CH, Sethi KD, Hauser RA et al. Ropinirole for the treatment of early Parkinson's disease: the ropinirole study group. Neurology 1997; 49: 393-399.
34. Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. Journal of neurology, neurosurgery, and psychiatry 2003; 74: 1071-1079.
35. Hughes DA, Bagust A, Haycox A et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001; 19: 1185-1197.
36. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Movement Disorders 2005; 20: 1397-1404.
37. Bull SA, Hu XH, Hunkeler EM et al. Discontinuation of use and switching of antidepressants: influence of patientphysician communication. JAMA: The Journal of the American Medical Association 2002; 288: 1403-1409.
38. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Movement Disorders 2004; 19: 513-517.
39. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapy 2001; 23: 1296-1310.
40. Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004; 62(1 Suppl. 1): S64-S71.
41. Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacapone - a review. Journal of Neural Transmission 2004; 111: 1343-1363.
42. Fenelon G, Gimenez-Roldan S, Montastruc JL et al. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. Journal of Neural Transmission 2003; 110: 239-251.